Douglas Ingram, who has led Sarepta Therapeutics since 2017, will retire by the end of 2026 or when a successor is found. The biotech company has faced significant challenges after two patient deaths linked to its gene therapy treatment Elevidys.
Douglas Ingram, the chief executive of Sarepta Therapeutics, plans to leave his position by the conclusion of 2026 or when a successor takes over, according to a company regulatory document filed Tuesday.
The biotechnology firm has begun searching for Ingram’s replacement, the filing stated.
Sarepta experienced a difficult 2025 following serious complications with Elevidys, its gene therapy treatment for muscular disorders, which resulted in two patient fatalities and declining revenue.
Federal health regulators requested that Sarepta voluntarily stop distributing Elevidys last year while investigating the deaths connected to the treatment.
The company responded to these setbacks by eliminating 500 positions and discontinuing development of multiple gene therapies targeting limb-girdle muscular dystrophy.
Elevidys now carries the FDA’s strongest safety alert and requires strict patient monitoring protocols following administration.
Speaking on Wednesday, Ingram acknowledged that “Elevidys has emerged from a challenging year,” noting the company is working on plans that could potentially expand access to patients who cannot walk.
The company’s stock value plummeted 82% during the previous year, and shares dropped an additional 4% in after-hours trading Wednesday.
Ingram has held the CEO position at Sarepta since 2017.
Tesla Fails to Take Steps for California Self-Driving Cars Despite Musk’s Claims
US Foundation Reports Chinese Social Media Campaign Targeting Elections Worldwide
New Poll Shows Americans Split on Trump’s Immigration Enforcement Methods